Staedtisches Klinikum Braunschweig gGmbH

At Staedtisches Klinikum Braunschweig gGmbH, a major share of the research program focuses on hemic and lymphatic diseases, especially acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. These studies are largely aimed at improving survival, deepening remission, and refining treatment choices for patients with newly diagnosed, relapsed, or hard-to-treat blood cancers.

• Testing new treatment combinations for acute myeloid leukemia and related marrow disorders
• Improving outcomes in acute lymphoblastic leukemia and lymphoblastic lymphoma, including pediatric and adult populations
• Evaluating novel approaches for multiple myeloma and aggressive lymphomas to strengthen disease control

The site’s work in this area reflects a strong interest in both intensive and lower-intensity strategies, with the goal of making blood cancer treatment more effective and better tailored to individual patients.

The site also conducts extensive research in neoplasms, with trials in prostate cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, bladder cancer, and gastric cancer. These studies are designed to test new therapies, compare treatment strategies, and improve control of advanced or recurrent disease.

• Assessing new options for metastatic castration-sensitive and metastatic castration-resistant prostate cancer
• Studying treatment approaches for stage III and advanced non-small cell lung cancer
• Exploring targeted and immune-based strategies for muscle-invasive bladder cancer and gastric cancer

Across these solid tumor programs, the emphasis is on improving survival, delaying progression, and finding better ways to match treatment with tumor biology.

Research in immune system diseases and related organ complications includes studies in lupus nephritis, systemic autoimmune rheumatic diseases associated interstitial lung disease, and chronic kidney disease. The purpose of these trials is to evaluate whether new therapies can better protect kidney function, reduce inflammation, and slow lung damage in people with complex autoimmune conditions.

• Testing new treatment approaches for active lupus nephritis to improve renal response
• Evaluating therapies for rheumatic disease-related interstitial lung disease and pulmonary fibrosis
• Studying kidney-protective strategies in chronic kidney disease to delay worsening and related complications

This area combines immune-focused research with practical goals such as preserving organ function and improving long-term quality of life.

The Medizinische Klinik III is involved in trials for children, adolescents, and young adults with cancers such as acute lymphoblastic leukemia, lymphoblastic lymphoma, medulloblastoma, and ependymoma. These studies aim to improve cure rates, reduce relapse risk, and refine treatment intensity for younger patients.

• Improving therapy for pediatric acute lymphoblastic leukemia and relapsed ALL
• Studying better treatment strategies for high-risk medulloblastoma and ependymoma
• Balancing effectiveness and long-term safety in childhood and adolescent cancer care

The research here focuses on giving younger patients more effective treatment while also considering the impact of therapy on future health.

Another important theme is male urogenital diseases and related reproductive and urinary physiological phenomena, especially in prostate cancer and bladder cancer. Trials in this area are looking at ways to delay progression, reduce recurrence, and improve disease monitoring in patients with localized, recurrent, or metastatic disease.

• Evaluating treatment strategies for high-risk and metastatic prostate cancer
• Studying new approaches in bladder cancer, including disease with specific genetic changes
• Improving detection of recurrence and treatment response in uro-oncology

These studies reflect a strong interest in personalized care for cancers of the urinary and reproductive systems.

A notable feature of the clinical trial portfolio is the use of response markers and biomarker-guided strategies across several disease areas, including hematologic malignancies, lung cancer, and prostate cancer. The goal is to improve treatment selection, assess effectiveness earlier, and better understand which patients benefit most from each therapy.

• Using disease markers to guide treatment decisions in leukemia and lymphoma
• Evaluating imaging- and biomarker-based approaches in prostate cancer and lung cancer
• Supporting more personalized treatment planning through response-adapted research

This research direction highlights the site’s interest in moving beyond standard treatment models toward more precise and individualized care.